How should Castleman disease be evaluated and managed, including differences between unicentric and multicentric forms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Castleman Disease: Evaluation and Management

Castleman disease requires immediate distinction between unicentric (UCD) and multicentric (MCD) forms, as this fundamentally determines treatment—UCD is managed with complete surgical excision when feasible, while MCD requires systemic therapy tailored to subtype (HHV-8-associated, POEMS-associated, or idiopathic).

Initial Evaluation and Diagnosis

Essential Diagnostic Workup

  • Excisional lymph node biopsy with comprehensive immunohistochemistry panel: CD20, CD3, CD10, BCL2, BCL6, Ki-67, CD138, kappa/lambda, HHV-8, and EBER-ISH 1
  • Imaging: CT chest/abdomen/pelvis with contrast; PET-CT for disease extent assessment 2
  • Laboratory panel: CBC with differential, comprehensive metabolic panel, LDH, C-reactive protein, IL-6, IL-10, serum protein electrophoresis 3, 4
  • HHV-8 serology and viral load to distinguish HHV-8-associated MCD 3, 5
  • HIV testing (HHV-8-associated MCD occurs predominantly in HIV-positive patients) 3, 6

Critical Distinction: UCD vs MCD

UCD involves a single lymph node region, typically asymptomatic or causing local compressive symptoms 2. MCD presents with multiple enlarged lymph node regions, systemic inflammatory symptoms (fever, night sweats, weight loss), and laboratory abnormalities (anemia, elevated inflammatory markers, hypergammaglobulinemia) 4.

Management of Unicentric Castleman Disease (UCD)

First-Line Treatment

Complete surgical resection is curative and the preferred treatment for all resectable UCD 2. This approach achieves excellent long-term outcomes with no recurrence in most cases 7, 2.

Unresectable UCD Management Algorithm

  1. Asymptomatic unresectable UCD: Observation with serial imaging is appropriate 2
  2. Symptomatic inflammatory syndrome: Siltuximab (anti-IL-6 monoclonal antibody) should be considered 2
  3. Compressive symptoms from mass effect:
    • Medical therapy (rituximab, corticosteroids) to reduce tumor size
    • Radiotherapy or embolization
    • Goal: render lesion amenable to surgical resection 2

Surgical Approach

Video-assisted thoracoscopic surgery (VATS) results in less blood loss (109 mL vs 522 mL) and shorter hospital stays (4 vs 7 days) compared to open thoracotomy, with similar complication rates and long-term outcomes 7.

Management of Multicentric Castleman Disease (MCD)

HHV-8-Associated MCD (in HIV-Positive Patients)

Rituximab monotherapy is the recommended first-line therapy 3. This recommendation is based on prospective studies and multicenter analyses demonstrating improved overall survival and disease-free survival compared to historical controls, with rapid decline in HHV-8 viremia, C-reactive protein, IL-6, and IL-10 3.

Treatment Algorithm for HHV-8-Associated MCD:

  1. Optimize antiretroviral therapy (ART) in all HIV-positive patients 3
  2. Mild-to-moderate disease: Rituximab monotherapy (standard dosing)
  3. Severe disease (including hemophagocytic syndrome or cytokine storm):
    • Rituximab + etoposide (can be added to first cycle to avoid flare) 3
    • If concurrent Kaposi sarcoma: Rituximab + liposomal doxorubicin (minimum 4 cycles) or etoposide 3

Important caveat: Rituximab should be used with caution in patients with CD4 count <50 cells/mm³; consider delaying after etoposide courses, though rituximab is associated with improved outcomes and reduces lymphoma risk 3.

Relapsed/Refractory HHV-8-Associated MCD:

  • Multiple rechallenges with rituximab-based therapy are safe and efficacious 3
  • Rituximab-refractory disease: Consider more aggressive chemotherapy regimens (e.g., CHOP) 3

Follow-Up Considerations:

  • Monitor for rituximab-associated Kaposi sarcoma reactivation/progression; add liposomal doxorubicin if this occurs 3
  • NHL incidence remains elevated despite rituximab, particularly HHV-8-associated NHL (PEL, DLBCL) 3
  • Clinical follow-up every 3-6 months 3

Idiopathic Multicentric Castleman Disease (iMCD)

Siltuximab (anti-IL-6 monoclonal antibody) with or without corticosteroids is the preferred first-line therapy for all iMCD patients 4. This represents the highest level of evidence-based recommendation from international consensus guidelines.

Disease Severity Stratification and Treatment Algorithm:

Mild-to-Moderate iMCD:

  • Siltuximab monotherapy (11 mg/kg IV every 3 weeks) 4
  • Alternative: Tocilizumab (anti-IL-6 receptor antibody) if siltuximab unavailable 4
  • May add corticosteroids for symptom control 4

Severe iMCD (organ dysfunction, severe cytopenias, anasarca):

  • Siltuximab + corticosteroids + combination chemotherapy (e.g., rituximab, cyclophosphamide) 4
  • Particularly important for iMCD-TAFRO subtype (thrombocytopenia, anasarca, fever, renal dysfunction, organomegaly), which presents with rapid-onset cytokine storm 8

iMCD Subtype-Specific Considerations:

iMCD-TAFRO (aggressive variant):

  • Requires early escalation to cyclosporine, rituximab, or chemotherapy 9, 8
  • Presents with severe inflammation, anasarca, thrombocytopenia, small-volume lymphadenopathy
  • Can mimic hemophagocytic lymphohistiocytosis or sepsis 8

iMCD-IPL (idiopathic plasmacytic lymphadenopathy):

  • Generally responds well to IL-6 blockade 9, 8
  • Presents with subacute/chronic lymphadenopathy, anemia, polyclonal hypergammaglobulinemia
  • May have elevated IgG4 (can mimic IgG4-related disease) 8

Second-Line Therapy for Refractory iMCD:

  1. Rituximab (B-cell depletion) 4, 10
  2. Cyclosporine (particularly for iMCD-TAFRO) 9
  3. Sirolimus (mTOR inhibitor)—emerging evidence shows mTORC1 hyperactivation in iMCD 9
  4. Cytotoxic chemotherapy (cyclophosphamide, etoposide) 4

Important note: Rituximab monotherapy can achieve clinical remission in iMCD when anti-IL-6 therapy is unavailable, though response may be delayed (biomarker improvement precedes clinical recovery) 10. Continue for adequate duration (up to 9 cycles over 24 months reported) before concluding treatment failure 10.

POEMS-Associated MCD

Management focuses on controlling the underlying plasma cell clone 9. Treatment approaches include:

  • Thalidomide or bortezomib (antimyeloma therapies) 8
  • Autologous stem cell transplantation in selected cases
  • Exclude POEMS syndrome when evaluating polyneuropathy in MCD patients 10

Response Criteria and Monitoring

Laboratory Monitoring During Treatment:

  • Serial measurements of inflammatory markers (CRP, IL-6, IL-10)
  • HHV-8 viral load (for HHV-8-associated MCD) 3
  • VEGF levels (particularly in iMCD with neurological involvement) 10
  • Complete blood counts (monitor for cytopenias)

Radiological Response Assessment:

  • CT or PET-CT after completion of therapy 3
  • Serial imaging for unresectable UCD under observation 2

Critical Pitfalls to Avoid

  1. Do not diagnose iMCD without excluding: HHV-8 infection, POEMS syndrome, lymphoma, autoimmune diseases (especially IgG4-related disease), and infections causing reactive lymphadenopathy 8, 4

  2. Do not use antivirals, immunomodulators, or IL-6-blocking agents as first-line therapy for HHV-8-associated MCD—these are of limited value compared to rituximab 3

  3. Do not delay systemic therapy in severe MCD (particularly iMCD-TAFRO) waiting for biopsy results if clinical presentation strongly suggests diagnosis—cytokine storm can be rapidly fatal 8

  4. Do not assume treatment failure with rituximab in iMCD if biomarkers improve but clinical symptoms persist—response may be delayed; continue therapy for adequate duration 10

  5. Do not overlook concurrent conditions: Kaposi sarcoma reactivation with rituximab in HHV-8+ patients 3, membranous nephropathy 10, or Sjögren's syndrome 10 in iMCD

  6. Do not use splenectomy except as last resort for severe refractory anemia/thrombocytopenia—provides only short-term symptom resolution 3

Prognosis

  • UCD: Excellent prognosis with complete surgical resection; 100% 5-year progression-free survival 7
  • HHV-8-associated MCD: 5-year survival improved to 88% in post-ART era with rituximab-based therapy 6
  • iMCD: Variable depending on subtype and severity; diabetes and clinical subtype are independent prognostic factors 7
  • MCD overall: 81.6% 5-year progression-free survival (significantly worse than UCD) 7

3, 9, 8, 7, 2, 4, 10

References

1
Guideline

nccn clinical practice guidelines in oncology: non-hodgkin's lymphomas.

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

6
Guideline

aids-related kaposi sarcoma, version 2.2019, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2019

8
Research

Expert Perspective: Diagnosis and Treatment of Castleman Disease.

Arthritis & rheumatology (Hoboken, N.J.), 2025

9
Research

Updates in the pharmacologic management of various Castleman disease subtypes: A comprehensive review.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2026

Related Questions

What is the pathogenesis of Castleman disease?
What is the recommended diagnostic workup and treatment for Castleman disease?
What are the differences in diagnosis and treatment between Castleman disease and Kikuchi disease?
What is the recommended treatment for an adult with multicentric Castleman disease presenting with systemic symptoms and widespread lymphadenopathy?
What is Castleman's disease?
In vascular Ehlers‑Danlos syndrome, is the risk of fatal arterial rupture a lifelong risk rather than only spontaneous events?
Is the arterial wall fragility in vascular Ehlers‑Danlos syndrome congenital (present from birth)?
What is the appropriate evaluation and management for a patient with a twisting injury of the left hip and leg who now has persistent left thigh and quadriceps pain and numbness extending from the knee to the ankle?
What does a positive QuantiFERON‑TB Gold Plus test indicate and what are the recommended steps for evaluation and treatment?
What are the genetics, inheritance pattern, and recommended genetic testing and counseling for Ehlers‑Danlos syndrome type VIIA (dermatosparaxis)?
What clinical features in a newborn or infant should raise suspicion for a COL1A1‑related connective tissue disorder such as osteogenesis imperfecta?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.